Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP.

DiJoseph JF, Dougher MM, Evans DY, Zhou BB, Damle NK.

Cancer Chemother Pharmacol. 2011 Apr;67(4):741-9. doi: 10.1007/s00280-010-1342-9. Epub 2010 Jun 3.

PMID:
20521053
2.

Antibody-drug conjugates ace the tolerability test.

Damle NK.

Nat Biotechnol. 2008 Aug;26(8):884-5. doi: 10.1038/nbt0808-884. No abstract available.

PMID:
18688241
3.

The oncofetal protein, 5T4, is a suitable target for antibody-guided anti-cancer chemotherapy with calicheamicin.

Boghaert ER, Sridharan L, Khandke KM, Armellino D, Ryan MG, Myers K, Harrop R, Kunz A, Hamann PR, Marquette K, Dougher M, DiJoseph JF, Damle NK.

Int J Oncol. 2008 Jan;32(1):221-34.

PMID:
18097562
4.

Determination of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 microl) blood samples.

Boghaert ER, Khandke KM, Sridharan L, Dougher M, DiJoseph JF, Kunz A, Hamann PR, Moran J, Chaudhary I, Damle NK.

Cancer Chemother Pharmacol. 2008 May;61(6):1027-35. Epub 2007 Aug 1.

PMID:
17668210
5.

Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia.

Dijoseph JF, Dougher MM, Armellino DC, Evans DY, Damle NK.

Leukemia. 2007 Nov;21(11):2240-5. Epub 2007 Jul 26.

PMID:
17657218
6.

CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab.

Dijoseph JF, Dougher MM, Armellino DC, Kalyandrug L, Kunz A, Boghaert ER, Hamann PR, Damle NK.

Cancer Immunol Immunother. 2007 Jul;56(7):1107-17. Epub 2006 Dec 12.

PMID:
17160682
7.

Biopharmaceutical drug discovery using novel protein scaffolds.

Gill DS, Damle NK.

Curr Opin Biotechnol. 2006 Dec;17(6):653-8. Epub 2006 Oct 19. Review.

PMID:
17055245
8.

Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy.

Boghaert ER, Khandke K, Sridharan L, Armellino D, Dougher M, Dijoseph JF, Kunz A, Hamann PR, Sridharan A, Jones S, Discafani C, Damle NK.

Int J Oncol. 2006 Mar;28(3):675-84.

PMID:
16465373
9.

Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma.

DiJoseph JF, Dougher MM, Kalyandrug LB, Armellino DC, Boghaert ER, Hamann PR, Moran JK, Damle NK.

Clin Cancer Res. 2006 Jan 1;12(1):242-9.

10.

B-cell depletion inhibits arthritis in a collagen-induced arthritis (CIA) model, but does not adversely affect humoral responses in a respiratory syncytial virus (RSV) vaccination model.

Dunussi-Joannopoulos K, Hancock GE, Kunz A, Hegen M, Zhou XX, Sheppard BJ, Lamothe J, Li E, Ma HL, Hamann PR, Damle NK, Collins M.

Blood. 2005 Oct 1;106(7):2235-43. Epub 2005 Jun 9.

11.

Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22.

DiJoseph JF, Popplewell A, Tickle S, Ladyman H, Lawson A, Kunz A, Khandke K, Armellino DC, Boghaert ER, Hamann P, Zinkewich-Peotti K, Stephens S, Weir N, Damle NK.

Cancer Immunol Immunother. 2005 Jan;54(1):11-24.

PMID:
15693135
12.

Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma.

DiJoseph JF, Goad ME, Dougher MM, Boghaert ER, Kunz A, Hamann PR, Damle NK.

Clin Cancer Res. 2004 Dec 15;10(24):8620-9.

13.

Tumour-targeted chemotherapy with immunoconjugates of calicheamicin.

Damle NK.

Expert Opin Biol Ther. 2004 Sep;4(9):1445-52. Review.

PMID:
15335312
14.

Antibody-targeted chemotherapy with the calicheamicin conjugate hu3S193-N-acetyl gamma calicheamicin dimethyl hydrazide targets Lewisy and eliminates Lewisy-positive human carcinoma cells and xenografts.

Boghaert ER, Sridharan L, Armellino DC, Khandke KM, DiJoseph JF, Kunz A, Dougher MM, Jiang F, Kalyandrug LB, Hamann PR, Frost P, Damle NK.

Clin Cancer Res. 2004 Jul 1;10(13):4538-49.

15.

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.

DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, Kunz A, Hamann PR, Gorovits B, Udata C, Moran JK, Popplewell AG, Stephens S, Frost P, Damle NK.

Blood. 2004 Mar 1;103(5):1807-14. Epub 2003 Nov 13.

16.

Antibody-targeted chemotherapy with immunoconjugates of calicheamicin.

Damle NK, Frost P.

Curr Opin Pharmacol. 2003 Aug;3(4):386-90. Review.

PMID:
12901947
17.

Reduced expression of EphrinA1 (EFNA1) inhibits three-dimensional growth of HT29 colon carcinoma cells.

Potla L, Boghaert ER, Armellino D, Frost P, Damle NK.

Cancer Lett. 2002 Jan 25;175(2):187-95.

PMID:
11741747
18.

Pharmacological inhibition of CD28-stimulated T cell activation.

Wancio D, Damle NK, Bansbach CC.

Inflamm Res. 1995 Aug;44 Suppl 2:S203-4. No abstract available.

PMID:
8548400
19.
20.

Costimulation of T-cell activation and virus production by B7 antigen on activated CD4+ T cells from human immunodeficiency virus type 1-infected donors.

Haffar OK, Smithgall MD, Bradshaw J, Brady B, Damle NK, Linsley PS.

Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11094-8.

21.
22.

Beta 2-integrin LFA-1 signaling through phospholipase C-gamma 1 activation.

Kanner SB, Grosmaire LS, Ledbetter JA, Damle NK.

Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7099-103.

24.

Bispecific receptor globulins, novel tools for the study of cellular interactions. Preparation and characterization of an E-selectin/P-selectin bispecific receptor globulin.

Dietsch MT, Smith VF, Cosand WL, Damle NK, Ledbetter JA, Linsley PS, Aruffo A.

J Immunol Methods. 1993 Jun 4;162(1):123-32.

PMID:
7685365
25.

Regulation of HIV production by blood mononuclear cells from HIV-infected donors: II. HIV-1 production depends on T cell-monocyte interaction.

Diegel ML, Moran PA, Gilliland LK, Damle NK, Hayden MS, Zarling JM, Ledbetter JA.

AIDS Res Hum Retroviruses. 1993 May;9(5):465-73.

PMID:
8100439
26.

Costimulation via vascular cell adhesion molecule-1 induces in T cells increased responsiveness to the CD28 counter-receptor B7.

Damle NK, Klussman K, Leytze G, Ochs HD, Aruffo A, Linsley PS, Ledbetter JA.

Cell Immunol. 1993 Apr 15;148(1):144-56.

PMID:
7684325
27.
28.

Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes.

Linsley PS, Greene JL, Tan P, Bradshaw J, Ledbetter JA, Anasetti C, Damle NK.

J Exp Med. 1992 Dec 1;176(6):1595-604.

29.

Differential regulatory effects of intercellular adhesion molecule-1 on costimulation by the CD28 counter-receptor B7.

Damle NK, Klussman K, Linsley PS, Aruffo A, Ledbetter JA.

J Immunol. 1992 Oct 15;149(8):2541-8.

PMID:
1383317
30.

GMP-140 (P-selectin/CD62) binds to chronically stimulated but not resting CD4+ T lymphocytes and regulates their production of proinflammatory cytokines.

Damle NK, Klussman K, Dietsch MT, Mohagheghpour N, Aruffo A.

Eur J Immunol. 1992 Jul;22(7):1789-93.

PMID:
1378017
31.

CD2/LFA-3 ligation induces phospholipase-C gamma 1 tyrosine phosphorylation and regulates CD3 signaling.

Kanner SB, Damle NK, Blake J, Aruffo A, Ledbetter JA.

J Immunol. 1992 Apr 1;148(7):2023-9.

PMID:
1372020
32.
35.

CTLA-4 is a second receptor for the B cell activation antigen B7.

Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA.

J Exp Med. 1991 Sep 1;174(3):561-9.

36.
37.
38.

Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation.

Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA.

J Exp Med. 1991 Mar 1;173(3):721-30.

40.

CD45 ligation in T cells regulates signal transduction through both the interleukin-2 receptor and the CD3/Ti T-cell receptor complex.

Gilliland LK, Schieven GL, Grosmaire LS, Damle NK, Ledbetter JA.

Tissue Antigens. 1990 Mar;35(3):128-35.

PMID:
2142837
42.

Antigen-specific suppressor T lymphocytes in man.

Damle NK, Engleman EG.

Clin Immunol Immunopathol. 1989 Nov;53(2 Pt 2):S17-24. Review.

PMID:
2551552
43.
46.
47.

Interleukin 2-activated killer lymphocytes in man.

Damle NK, Bradley EC.

Year Immunol. 1988;3:138-43. Review. No abstract available.

PMID:
3327308
49.

Immunoregulatory T lymphocytes in man. Soluble antigen-specific suppressor-inducer T lymphocytes are derived from the CD4+CD45R-p80+ subpopulation.

Damle NK, Childs AL, Doyle LV.

J Immunol. 1987 Sep 1;139(5):1501-8. Erratum in: J Immunol 1987 Dec 1;139(11):3911.

PMID:
2887618
50.

Supplemental Content

Loading ...
Support Center